The increased dipeptidyl peptidase‐4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin‐treated patients

Aim: Dipeptidyl peptidase (DPP)‐4 in responsible for incretin degradation and some observations suggest that DPP‐4 activity is increased in type 2 diabetes (T2D). We aimed to assess the effect of T2D and glucose control on DPP‐4 activity.

[1]  M. Marescotti,et al.  Optimized glycaemic control achieved with add‐on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine , 2011, Diabetes, obesity & metabolism.

[2]  J. Holst,et al.  Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. , 2011, Endocrinology.

[3]  J. Holst,et al.  Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs , 2011, Diabetologia.

[4]  J. Kaufman,et al.  Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome , 2011, Diabetes.

[5]  J. Teixeira,et al.  Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase‐4 activity in obese patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[6]  B. Charbonnel,et al.  Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies , 2011, Diabetes, obesity & metabolism.

[7]  S. Patterson,et al.  Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. , 2011, Metabolism: clinical and experimental.

[8]  Yup Kang,et al.  Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes. , 2010, Diabetes research and clinical practice.

[9]  J. Féher,et al.  Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker , 2010, PloS one.

[10]  A. Avogaro,et al.  The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes , 2010, Diabetes Care.

[11]  S. Patterson,et al.  Investigation of the effect of oral metformin on dipeptidylpeptidase‐4 (DPP‐4) activity in Type 2 diabetes 1 , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[12]  K. Tsuda,et al.  GLUCOSE REGULATION OF DIPEPTIDYL PEPTIDASE IV GENE EXPRESSION IS MEDIATED BY HEPATOCYTE NUCLEAR FACTOR‐1α IN EPITHELIAL INTESTINAL CELLS , 2008, Clinical and experimental pharmacology & physiology.

[13]  J. Lindsay,et al.  Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. , 2008, Diabetes research and clinical practice.

[14]  J. A. Davis,et al.  Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice. , 2007, Life sciences.

[15]  Sten Madsbad,et al.  Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. , 2006, European journal of endocrinology.

[16]  J. Holst,et al.  Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans , 2006, Diabetologia.

[17]  P. Flatt,et al.  Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[18]  E. Mannucci,et al.  Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus , 2005, Diabetologia.

[19]  J. Lenhard,et al.  Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. , 2004, Biochemical and biophysical research communications.

[20]  Y. S. Kim,et al.  Biosynthesis and degradation of altered immature forms of intestinal dipeptidyl peptidase IV in a rat strain lacking the enzyme. , 1992, The Journal of biological chemistry.

[21]  N. Thompson,et al.  A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Use as a liver-cell transplantation model. , 1991, The Biochemical journal.